Showing 2241-2260 of 8668 for: Cochrane Systematic Reviews Back
- Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children
Cochrane Systematic Reviews, 10-Jan-2018
Tonic-clonic convulsions and convulsive status epilepticus (currently defined as a tonic-clonic convulsion lasting at least 30 minutes) are medical emergencies and require urgent and appropriate anticonvulsant treatment. International consensus is that an
- Drug therapies for reducing gastric acidity in people with cystic fibrosis
Cochrane Systematic Reviews, 27-Apr-2021
Malabsorption of fat and protein contributes to poor nutritional status in people with cystic fibrosis. Impaired pancreatic function may also result in increased gastric acidity, leading in turn to heartburn, peptic ulcers and the impairment of oral pancr
- Drug therapy for chronic idiopathic axonal polyneuropathy
Cochrane Systematic Reviews, 20-Jun-2017
Chronic idiopathic axonal polyneuropathy (CIAP) is an insidiously progressive sensory or sensorimotor polyneuropathy that affects elderly people. Although severe disability or handicap does not occur, CIAP reduces quality of life. CIAP is diagnosed in 10%
- Drug therapy for delirium in terminally ill adults
Cochrane Systematic Reviews, 21-Jan-2020
Delirium is a syndrome characterised by an acute disturbance of attention and awareness which develops over a short time period and fluctuates in severity over the course of the day. It is commonly experienced during inpatient admission in the terminal ph
- Drug therapy for obstructive sleep apnoea in adults
Cochrane Systematic Reviews, 30-Apr-2013
The treatment of choice for moderate to severe obstructive sleep apnoea (OSA) is continuous positive airways pressure (CPAP) applied via a mask during sleep. However, this is not tolerated by all individuals and its role in mild OSA is not proven. Drug th
- Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease
Cochrane Systematic Reviews, 5-Jun-2013
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is the most common neurodegenerative disorder of the motor system in adults. Pain in ALS is a frequent symptom especially in the later stages of disease and can have a pronounc
- Drug therapy for preventing post‐dural puncture headache
Cochrane Systematic Reviews, 28-Feb-2013
Post-dural (post-lumbar or post-spinal) puncture headache (PDPH) is one of the most common complications of diagnostic, therapeutic or inadvertent lumbar punctures. Many drug options have been used to prevent headache in clinical practice and have also be
- Drug therapy for symptoms associated with anxiety in adult palliative care patients
Cochrane Systematic Reviews, 18-May-2017
This is an update of a Cochrane Review first published in 2004 (Issue 1) and previously updated in 2012 (Issue 10). Anxiety is common in palliative care patients. It can be a natural response to the complex uncertainty of having a life-limiting illness or
- Drug therapy for the management of cancer-related fatigue
Cochrane Systematic Reviews, 1-Aug-2010
This review is an update of a previously published review in The Cochrane Database of Systematic Reviews (Issue 1 2008). Cancer-related fatigue (CRF) is common, under-recognised and difficult to treat. There have been studies looking at drug interventions
- Drug therapy for treating post‐dural puncture headache
Cochrane Systematic Reviews, 15-Jul-2015
This is an updated version of the original Cochrane review published in Issue 8, 2011, on 'Drug therapy for treating post-dural puncture headache'.
- Drug treatment for facioscapulohumeral muscular dystrophy
Cochrane Systematic Reviews, 19-Apr-2004
Facioscapulohumeral muscular dystrophy is a progressive muscle disease which has no agreed treatment. Early suggestions that corticosteroids might be helpful were not supported by a subsequent open label study. The beta 2 adrenergic agonist albuterol, als
- Drug treatment for faecal incontinence in adults
Cochrane Systematic Reviews, 11-Jun-2013
Faecal incontinence (leakage of bowel motions or stool) is a common symptom which causes significant distress and reduces quality of life.
- Drug treatment for myotonia
Cochrane Systematic Reviews, 10-May-2011
Abnormal delayed relaxation of skeletal muscles, known as myotonia, can cause disability in myotonic disorders. Sodium channel blockers, tricyclic antidepressive drugs, benzodiazepines, calcium-antagonists, taurine and prednisone may be of use in reducing
- Drug treatment for spinal muscular atrophy type I
Cochrane Systematic Reviews, 11-Dec-2019
Spinal muscular atrophy (SMA) is caused by a homozygous deletion of the survival motor neuron 1 (SMN1) gene on chromosome 5, or a heterozygous deletion in combination with a point mutation in the second SMN1 allele. This results in degeneration of anterio
- Drug treatment for spinal muscular atrophy types II and III
Cochrane Systematic Reviews, 6-Jan-2020
Spinal muscular atrophy (SMA) is caused by a homozygous deletion of the survival motor neuron 1 (SMN1) gene on chromosome 5, or a heterozygous deletion in combination with a (point) mutation in the second SMN1 allele. This results in degeneration of anter
- Drug treatments for managing cystic fibrosis‐related diabetes
Cochrane Systematic Reviews, 19-Oct-2020
The Cystic Fibrosis Foundation recommends both short-term and long-acting insulin therapy when cystic fibrosis-related diabetes (CFRD) has been diagnosed. Diagnosis is based on: an elevated fasting blood glucose level greater than 6.94 mmol/L (125 mg/dL);
- Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs
Cochrane Systematic Reviews, 4-Aug-2016
Atherosclerotic peripheral arterial disease (PAD) can lead to disabling ischemia and limb loss. Treatment modalities have included risk factor optimization through life-style modifications and medications, or operative approaches using both open and minim
- Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in‐stent restenosis of the femoropopliteal arteries
Cochrane Systematic Reviews, 26-Jan-2019
Stents are placed in the femoropopliteal arteries for numerous reasons, such as atherosclerotic disease, the need for dissection, and perforation of the arteries, and can become stenosed with the passage of time. When a stent develops a flow-limiting sten
- Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes
Cochrane Systematic Reviews, 20-Oct-2015
Coronary artery stents are tiny tubular devices used to 'scaffold' vessels open during percutaneous transluminal coronary angioplasty (PTCA). Restenosis (re-narrowing) of vessels treated with stents is a problem; in order to reduce restenosis, stents that
- Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome
Cochrane Systematic Reviews, 23-Aug-2017
Approximately 3.7 million people died from acute coronary syndrome worldwide in 2012. Acute coronary syndrome, also known as myocardial infarction or unstable angina pectoris, is caused by a sudden blockage of the blood supplied to the heart muscle. Percu
